|
| Author | Type of study | Population | Duration of enrollment | Number of patients | Countries | Midodrine dose | Main results |
|
| Liu, 2010 | Retrospective (abstract) | Patients requiring IVV for septic shock | December 2007 to December 2009 | 40 | USA | — | Midodrine decreased the duration of IVV |
|
| Poveromo, 2016 | Retrospective | Patients requiring IVV | January 2007 to March 2012 | 188 | USA | 10 mg every 8 hours (starting dose) | Midodrine increased hospital LOS and did not affect ICU LOS or ICU readmissions. Bradycardia occurred in 12.8% in midodrine group compared to 0% in control group |
|
| Whitson, 2016 | Retrospective | Patients with septic shock requiring at least 24 h of IVV | November 2013 to November 2014 | 275 | USA | 10 mg every 8 hours (starting dose) | Midodrine decreased duration of IVV, reinstitution of IVV, and ICU LOS. No significant difference in bradycardia rates |
|
| Roach, 2017 | Retrospective (abstract) | Patients requiring at least 7 days of IVV | September 2013 to September 2016 | 2070 | USA | 15 mg every 8 hours (starting dose) | Midodrine did not significantly decrease duration of IVV, hospital LOS, or ICU LOS. No significant difference in bradycardia rates |
|
| Fiorenza, 2019 | Retrospective (abstract) | Patients who received less than 15 mcg/hr of norepinephrine equivalent after extubation | December 2016 to June 2018 | 44 | USA | — | Midodrine decreased hospital LOS, ICU readmission, and vasopressors reinstitution |
|
| Nadhim, 2019 | Retrospective (abstract) | Patients with septic shock requiring at least 24 h of IVV | January 2017 to March 2018 | 83 | USA | — | Midodrine did not significantly decrease the duration of IVV |
|
| Hailu, 2020 | Retrospective (abstract) | Patients with septic shock requiring at least 24 h of IVV | June 2013 to August 2018 | 166 | USA | — | Midodrine decreased ICU LOS, hospital LOS, and IVV duration |
|
| Tremblay, 2020 | Retrospective | Patients requiring IVV within the first week after cardiac surgery with cardiopulmonary bypass | January 2014 to January 2018 | 148 | Canada | 10 mg every 8 hours (starting dose) | Midodrine increased ICU LOS and was associated with higher mortality |
|
| Santer, 2020 (MIDAS) | Randomized controlled trial | Patients (adults) requiring single-agent IVV for more than 24 h | October 2012 to June 2019 | 132 | USA and Australia | 20 mg every 8 hours | Midodrine did not decrease time to IV vasopressors discontinuation and was associated with more bradycardia |
|
